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Introduction: In the last decade, there has been a great interest in the c-erbB-2 or
Her-2/neu proto-oncogene with regard to tumour biology in a large spectrum of
malignancies. The C-erbB-2 proto-oncogene is located on the long arm of
chromosome 17 and encodes a transmembrane tyrosine kinase growth factor
that has similarities to the epidermal growth factor receptor [1]. The largest study
investigating c-erbB-2 in endometrial cancer found overexpression in 15% of
cases [2]. However, serous endometrial cancer showed overexpression of c-erbB-
2 in 60% [3]. Given the signiﬁcant c-erbB-2 overexpression in aggressive
endometrial cancer, we investigated whether uterine sarcomas showed a similar
pattern.
Patients and methods: All cases of uterine sarcomas that we encountered in our
database from January 1990 to July 2003 were included. After central review,
representative biopsies were immunohistochemically stained for c-erbB-2 (anti-
HER-2/neu monoclonal antibody, DAKO). Only biopsies of carcinosarcoma
with presence of both the epithelial and mesenchymal components were
included. C-erbB-2 positivity was graded as follows: negative ()), weakly
positive (+), moderately positive (++) and strongly positive (+++). Only
membrane staining was considered positive. The carcinoma and sarcoma
components of carcinosarcomas were analysed separately. Fluorescent in situ
hybridisation (FISH) was performed on cases with c-erbB-2 overexpression.
Results: Seventy uterine sarcomas originating from 59 patients were evaluated
(52 primaries and 18 recurrent). Absence of c-erbB-2 overexpression was noted
in 10 adenosarcomas (9 primaries, 1 recurrence), in 21 ESS (10 primaries, 11
recurrences), and 10 leiomyosarcomas (7 primaries, 3 recurrences). Among
patients with undiﬀerentiated sarcomas, 1/4 (25%) stained 2+ and positivity was
conﬁrmed in the recurrent tumour (3+). Twenty-two primary carcinosarcomas
were scored. The epithelial component was negative in 7 cases (32%), 1+ in 9
(41%), 2+ in 4 (18%), 3+ in 1 (5%) and could not be evaluated in one case,
whereas the sarcoma component stained negative in 18 cases (82%), 1+ in 3
(14%) and 3+ in one (5%) case. In two recurrent carcinosarcomas, the epithelial
component stained 3+ in both cases, whereas the sarcoma component scored
negative and 1+.
Ampliﬁcation of c-erbB-2, as determined by FISH, was observed in 5 cases with
2+ or 3+ overexpression.
Discussion: This study was the ﬁrst to investigate c-erbB-2 in undiﬀerentiated
uterine sarcomas and showed immunohistochemical overexpression and ampli-
ﬁcation of the c-erbB-2 gene in 1/4 (25%) of cases. The lack of eﬃcient treatment
modalities in this highly aggressive disease might be of clinical importance. In
addition, we performed the ﬁrst analysis of c-erbB-2 in endometrial stromal
sarcomas, although the results suggest absence of c-erbB-2 overexpression in this
tumour type.
In the recurrent setting, we observed overexpression and ampliﬁcation of c-erbB-
2 in 2/2 carcinosarcomas and one undiﬀerentiated sarcoma. The observation that
one of these carcinosarcomas stained negative in the primary tumour, suggests a
shift of regulators controlling the cell cycle during tumour evolution. The
hypothesis that c-erbB-2 mainly contributes to the malignant cell cycle in
the recurrent setting, needs to be conﬁrmed in a larger number of cases, but given
the need for eﬀective treatment regimens in this setting might be of clinical
relevance.
In uterine carcinosarcoma, 5/22 (22.5%) of cases showed overexpression of the c-
erbB-2 gene. Given the toxicity proﬁle of the most active agents, including
cisplatin and ifosfamide, our data might suggest a role for trastuzumab in the
treatment of this tumour type. Furthermore, the synergy between cisplatin and
anti-c-erbB-2 antibodies observed in breast cancer [4], might also be applicable
for uterine carcinosarcomas.
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